期刊文献+

Osteopontin is an important mediator of alcoholic liver disease via hepatic stellate cell activation 被引量:6

Osteopontin is an important mediator of alcoholic liver disease via hepatic stellate cell activation
下载PDF
导出
摘要 AIM: To investigate over-expression of Osteopontin(OPN) pathway expression and mechanisms of action in human alcoholic liver disease(ALD), in vivo and in vitro acute alcohol models. METHODS: OPN pathway was evaluated in livers from patients with progressive stages of human ALD and serum from drinkers with and without liver cirrhosis. In vitro stellate LX2 cells exposed to acute alcohol and in vivo in acute alcoholic steatosis mouse models were also investigated for OPN pathway expression and function. WT and OPN-/- mice were administered an acute dose of alcohol and extent of liver injury was examined by histopathology and liver biochemistry after 16-24 h. The causative role of OPN was studied in OPN knockout animals and in vitro in stellate LX2 cells, utilizing siRNA, aptamer and neutralizing antibodies to block OPN and OPN pathway. OPN pathway expression and downstream functional consequences were measured for signaling by Western blotting, plasmin activation by spectrophotometric assays and cell migration by confocal imaging and quantitation. RESULTS: OPN expression positively correlated with disease severity in patients with progressive stages of ALD. In vivo, associated with alcoholic steatosis, a single dose of acute alcohol significantly increased hepatic OPN mRNA and protein, and a cleaved OPN form in a dose dependent manner. OPN mRNA and secreted OPN also increased in parallel with activation of LX2 stellate cells within 4 h of a single dose of alcohol. Expression of OPN receptors, αvβ3-integrin and CD44, increased in human ALD, and in vivo and in vitro with alcohol administration. This was accompanied by downstream phosphorylation of Akt and Erk, increased mRNA expression of several fibrogenesis, fibrinolysis and extracellular matrix pathway genes, plasmin activation and hepatic stellate cell(HSC) migration. Inhibition of OPN and OPN-receptor mediated signaling partially inhibited alcohol-induced HSC activation, plasmin activity and cell migration. CONCLUSION: OPN is a key mediator of the alcoholinduced effects on hepatic stellate cell functions and liver fibrogenesis. AIM: To investigate over-expression of Osteopontin (OPN) pathway expression and mechanisms of action in human alcoholic liver disease (ALD), in vivo and in vitro acute alcohol models.
出处 《World Journal of Gastroenterology》 SCIE CAS 2014年第36期13088-13104,共17页 世界胃肠病学杂志(英文版)
基金 Supported by Philanthropic Anonymous Source the University of Sydney Bridging Support Grant,in part for Honours Project Supported by the National Health and Medical Research Council,No.NHMRC Practitioner Research Fellowship for PH support
关键词 HEPATIC stellate cells Liver CIRRHOSIS PLASMIN Ste Hepatic stellate cells Liver cirrhosis Plasmin Steatosis Fibrogenesis Transforming growth factor &#x003b2 Osteopontin isoform
  • 相关文献

参考文献11

  • 1Renee J Phillips,Karla J Helbig,Kylie H Van der Hoek,Devanshi Seth,Michael R Beard.Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner[J].World Journal of Gastroenterology,2012,18(26):3389-3399. 被引量:12
  • 2Xiao Xiao,Yi Gang,Yong Gu,Lina Zhao,Jindong Chu,Jinfeng Zhou,Xiqiang Cai,Hui Zhang,Li Xu,Yongzhan Nie,Kaichun Wu,Zhiguo Liu,Daiming Fan.Osteopontin Contributes to TGF-β1 Mediated Hepatic Stellate Cell Activation[J].Digestive Diseases and Sciences.2012(11)
  • 3Susan R.Rittling,Hiroko N.Matsumoto,Marc D.Mckee,AntonioNanci,Xiao‐RongAn,Kristine E.Novick,Aaron J.Kowalski,MasakiNoda,David T.Denhardt.Mice Lacking Osteopontin Show Normal Development and Bone Structure but Display Altered Osteoclast Formation In Vitro[J].J Bone Miner Res.2009(7)
  • 4Wing–Kin Syn,Youngmi Jung,Alessia Omenetti,Manal Abdelmalek,Cynthia D. Guy,Liu Yang,Jiangbo Wang,Rafal P. Witek,Caitlin M. Fearing,Thiago A. Pereira,Vanessa Teaberry,Steve S. Choi,J. Conde–Vancells,Gamze F. Karaca,Anna Mae Diehl.Hedgehog-Mediated Epithelial-to-Mesenchymal Transition and Fibrogenic Repair in Nonalcoholic Fatty Liver Disease[J].Gastroenterology.2009(4)
  • 5Sujin Chae,Hyoung-Oh Jun,Eun Lee,Suk-Jin Yang,Dong Lee,Joon Jung,Kyung Park,Young Yeom,Kyu-Won Kim.Osteopontin splice variants differentially modulate the migratory activityof hepatocellular carcinoma cell lines[J].International Journal of Oncology.2009(6)
  • 6Devanshi Seth,Philip J. Hogg,Mark D. Gorrell,Geoffrey W. McCaughan,Paul S. Haber.Direct effects of alcohol on hepatic fibrinolytic balance: Implications for alcoholic liver disease[J].Journal of Hepatology.2008(4)
  • 7RikuDas,SubhaPhilip,Ganapati H.Mahabeleshwar,AnuradhaBulbule,Gopal C.Kundu.Osteopontin: It’s Role in Regulation of Cell Motility and Nuclear Factor κB‐mediated Urokinase Type Plasminogen Activator Expression[J].IUBMB Life.2008(6)
  • 8Devanshi Seth,Mark D. Gorrell,Shaun Cordoba,Geoffrey W. McCaughan,Paul S. Haber.Intrahepatic gene expression in human alcoholic hepatitis[J].Journal of Hepatology.2006(2)
  • 9Udayan M. Apte,Atrayee Banerjee,Rachel McRee,Elizabeth Wellberg,Shashi K. Ramaiah.Role of osteopontin in hepatic neutrophil infiltration during alcoholic steatohepatitis[J].Toxicology and Applied Pharmacology.2004(1)
  • 10Sung Hee Lee,Geom Seog Seo,Young Nyun Park,Tae Moo Yoo,Dong Hwan Sohn.Effects and regulation of osteopontin in rat hepatic stellate cells[J].Biochemical Pharmacology.2004(12)

二级参考文献40

  • 1Okuda K. Hepatocellular carcinoma. J Hepatol 2000; 32: 225-237.
  • 2Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94:153-156.
  • 3Wong CM, Ng IO. Molecular pathogenesis of hepatocellular carcinoma. Liver Int 2008; 28:160-174.
  • 4Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepa- tocellular carcinoma. Clin Liver Dis 2005; 9: 191-211, v.
  • 5EI-Serag HB, Rudolph KL. Hepatocellular carcinoma: epi- demiology and molecular carcinogenesis. Gastroenterology 2007; 132:2557-2576.
  • 6Gotoh M, Sakamoto M, Kanetaka K, Chuuma M, Hirohashi S. Overexpression of osteopontin in hepatocellular carci- noma. Pathol Int 2002; 52:19-24.
  • 7Xie H, Song J, Du R, Liu K, Wang J, Tang H, Bai F, Liang J, Lin T, Liu J, Fan D. Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma. Dig Liver Dis 2007; 39:167-172.
  • 8Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY, Wang XW. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003; 9: 416-423.
  • 9Sun BS, Dong QZ, Ye QH, Sun HJ, Jia HL, Zhu XQ, Liu DY, Chen J, Xue Q, Zhou HJ, Ren N, Qin LX. Lentiviral-mediat- ed miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatol- ogy 2008; 48:1834-1842.
  • 10Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 2006; 16:79-87.

共引文献12

同被引文献51

  • 1Roberto de Franchis.Revising consensus in portal hypertension: Report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension[J].Journal of Hepatology.2010(4)
  • 2Gennaro D’Amico,Guadalupe Garcia-Tsao,Luigi Pagliaro.Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies[J].Journal of Hepatology.2005(1)
  • 3Jaime Bosch,Juan Abraldes,Annalisa Berzigotti,Juan Garcia-Pagan.Portal Hypertension and Gastrointestinal Bleeding[J].Semin Liver Dis.2008(01)
  • 4Juan G. Abraldes,Ilaria Tarantino,Juan Turnes,Juan Carlos Garcia-Pagan,Juan Rodés,Jaime Bosch.Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis[J]. Hepatology . 2003 (4)
  • 5Cristina Ripoll,Roberto Groszmann,Guadalupe Garcia–Tsao,Norman Grace,Andrew Burroughs,Ramon Planas,Angels Escorsell,Juan Carlos Garcia–Pagan,Robert Makuch,David Patch,Daniel S. Matloff,Jaime Bosch.??<ce:link locator='fx1'/> Hepatic Venous Pressure Gradient Predicts Clinical Decompensation in Patients With Compensated Cirrhosis(J)Gastroenterology . 2007 (2)
  • 6Sufen Shang,Amelie Plymoth,Shaokui Ge,Ziding Feng,Hugo R. Rosen,Suleeporn Sangrajrang,Pierre Hainaut,Jorge A. Marrero,Laura Beretta.??Identification of osteopontin as a novel marker for early hepatocellular carcinoma(J)Hepatology . 2012 (2)
  • 7Gennaro D’Amico,Juan Carlos Garcia-Pagan,Angelo Luca,Jaime Bosch.??Hepatic Vein Pressure Gradient Reduction and Prevention of Variceal Bleeding in Cirrhosis: A Systematic Review(J)Gastroenterology . 2006 (5)
  • 8Roberto J. Groszmann,Suchat Wongcharatrawee.??The hepatic venous pressure gradient: Anything worth doing should be done right(J)Hepatology . 2004 (2)
  • 9Martina Buck,Guadalupe Garcia‐Tsao,Roberto J. Groszmann,Caitlin Stalling,Norman D. Grace,Andrew K. Burroughs,David Patch,Daniel S. Matloff,Paul Clopton,Mario Chojkier.??Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients(J)Hepatology . 2014 (3)
  • 10Sumiko Nagoshi.??Osteopontin: Versatile modulator of liver diseases(J)Hepatol Res . 2014 (1)

引证文献6

二级引证文献37

  • 1王珍(综述),卢焕元(审校),刘晟(审校).CT和MR在无创门静脉压力测量方面的应用及研究进展[J].临床放射学杂志,2020,39(3):626-629. 被引量:3
  • 2无,祁小龙,张春清.中国肝静脉压力梯度临床应用专家共识(2018版)[J].胃肠病学和肝病学杂志,2018,27(12):1329-1340. 被引量:1
  • 3章晓云,邓俊黎,张霓,王静,颜瑾,叶婷.武汉地区肝硬化病人的饮食行为习惯与其预后的关系研究[J].护理研究(中旬版),2017,31(2):621-623. 被引量:3
  • 4吴剑平,肖海英,郑雪莲,汪安江.白介素25及其相关因子在肝纤维化中的作用[J].基础医学与临床,2018,38(10):1461-1465. 被引量:2
  • 5中国门静脉高压诊断与监测研究组(CHESS),中华医学会消化病学分会微创介入协作组,中目医师协会介入医师分会急诊介入专业委员会,中华医学会消化病学分会肝胆疾病协作组,中华医学会外科学分会脾脏及门静脉高压学组,中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国研究型医院学会肝病专业委员会,中华预防医学会肝胆胰疾病预防与控制专业委员会,中华医学会数字医学分会,中华医学会临床流行病学和循证医学分会,祁小龙,张春清.中国肝静脉压力梯度临床应用专家共识(2018版)[J].中华放射学杂志,2018,52(11):811-822. 被引量:9
  • 6中国门静脉高压诊断与监测研究组(CHESS),中华医学会消化病学分会微创介入协作组,中国医师协会介入医师分会急诊介入专业委员会,中华医学会消化病学分会肝胆疾病协作组,中华医学会外科学分会脾脏及门静脉高压学组,中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国研究型医院学会肝病专业委员会,中华预防医学会肝胆胰疾病预防与控制专业委员会,中华医学会数字医学分会,中华医学会临床流行病学和循证医学分会,祁小龙,张春清.中国肝静脉压力梯度临床应用专家共识(2018版)[J].中华消化外科杂志,2018,17(11):1059-1070. 被引量:17
  • 7中国门静脉高压诊断与监测研究组(CHESS),中华医学会消化病学分会微创介入协作组,中国医师协会介入医师分会急诊介入专委会,中华医学会外科学分会脾脏及门静脉高压学组,中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国研究型医院学会肝病专业委员会,中华预防医学会肝胆胰疾病预防与控制专业委员会,中华医学会数字医学分会,中华医学会临床流行病学和循证医学分会,祁小龙,张春清.中国肝静脉压力梯度临床应用专家共识(2018版)[J].中华肝脏病杂志,2018,26(11):801-812. 被引量:35
  • 8宋珂达,姜洪池.门静脉压力无创测定应给予重视[J].中华普通外科学文献(电子版),2018,12(6):373-375. 被引量:5
  • 9中国门静脉高压诊断与监测研究组(CHESS),中华医学会消化病学分会微创介入协作组,中国医师协会介入医师分会急诊介入专业委员会,中华医学会消化病学分会肝胆疾病协作组,中华医学会外科学分会脾脏及门静脉高压学组,中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国研究型医院学会肝病专业委员会,中华预防医学会肝胆胰疾病预防与控制专业委员会,中华医学会数字医学分会,中华医学会临床流行病学和循证医学分会,祁小龙,张春清.中国肝静脉压力梯度临床应用专家共识(2018版)[J].中华消化杂志,2018,38(11):728-738. 被引量:45
  • 10中国门静脉高压诊断与监测研究组,中华医学会消化病学分会微创介入协作组,中国医师协会介入医师分会急诊介入专委会,中华医学会消化病学分会肝胆疾病协作组,中华医学会外科学分会脾脏及门静脉高压学组,中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国研究型医院学会肝病专业委员会,中华预防医学会肝胆胰疾病预防与控制专业委员会,中华医学会数字医学分会,中华医学会临床流行病学和循证医学分会,祁小龙,张春清.中国肝静脉压力梯度临床应用专家共识(2018版)[J].中华肝胆外科杂志,2018,24(11):721-732. 被引量:6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部